Research Papers and Presentations

November 2019
Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab
Poster Presentation
Society for Immunotherapy of Cancer (SITC) annual meeting
National Harbor, MD

Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy
Poster Presentation
Society for Immunotherapy of Cancer (SITC) annual meeting
National Harbor, MD

June 2019
IMPRIME 1: An Open Label, Multicenter Ph2 Study Combining Imprime PGG with Pembrolizumab (pembro) in Previously Treated, Metastatic Triple Negative Breast Cancer (mTNBC)
Poster Presentation
American Society of Clinical Oncology annual meeting
Chicago

April 2019
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers
A peer-reviewed paper
Journal of Immunology 

December 2018
Imprime PGG, a Novel Innate Immune Modulator, Combined with Pembrolizumab in a Phase 2 Multicenter, Open Label Study in Chemotherapy-resistant Metastatic Triple Negative Breast Cancer (TNBC)
Poster Presentation
San Antonio Breast Cancer Symposium
San Antonio, Texas

November 2018
Treatment with Imprime PGG, a Soluble Yeast β-glucan PAMP, Induces Trafficking of Activated Ly6Ghigh Cells to Secondary Lymphoid Organs and Tumor and Facilitates Immune Activation within the Tumor Microenvironment
Poster Presentation
AACR Tumor Immunology and Immunotherapy Conference
Miami Beach, Florida

Imprime PGG, a Soluble Yeast β-glucan PAMP, Converts the Immunosuppressive Myeloid Tumor Microenvironment into an Immunoactive One: Translation of Preclinical Findings to Melanoma and Triple-Negative Breast Cancer (TNBC) Patients
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Poster Presentation
Dublin

Immunopharmacodynamic (IPD) Responses of Imprime PGG Combined with Pembrolizumab in Chemotherapy-Resistant, Metastatic Triple Negative Breast Cancer (TNBC) Subjects in a Phase 2 Trial: Analyses of Stage 1 Patients
Poster Presentation
Society for Immunotherapy of Cancer (SITC) annual meeting
Washington. D.C.

Imprime PGG, a Novel Cancer Immunotherapeutic, Engages the Complement System to Prime Innate Immune Effector Functions
Poster Presentation
Society for Immunotherapy of Cancer (SITC) annual meeting
Washington. D.C.

October 2018
Imprime PGG, a Systemically Administered PAMP, Mobilizes Monocytes in the Periphery, Facilitates Their Trafficking to the Tumor Site and Polarizes the Tumor Microenvironment (TME) to an Immuno-active State
Poster Presentation
CRI-CIMT-EATI-AACR International Cancer lmmunotherapy Conference: Translating Science into Survival
New York

April 2018
Imprime PGG (β-1,3/1,6 glucan) Synergizes with a CD40 Agonist to Stimulate T Cell Dependent Anti-tumor Activity in a Poorly Immunogenic Model of Pancreatic Carcinoma
Poster Presentation
American Association for Cancer Research Annual Meeting
Chicago

Imprime PGG, a Soluble Yeast β-glucan PAMP, Enhancement of Anti-tumor Responses in Combination with Tumor Targeting Antibody is Highly Dependent on NK Cell Killing
Poster Presentation
American Association for Cancer Research Annual Meeting
Chicago

Imprime PGG, a Soluble Yeast β-glucan PAMP, in Combination with Pembrolizumab Induces Infiltration and Activation of Both Innate and Adaptive Immune Cells Within Tumor Sites in Melanoma and Triple-Negative Breast Cancer (TNBC) Patients
Poster Presentation
American Association for Cancer Research Annual Meeting
Chicago

March 2018
Imprime PGG Modulates the Functionality of Immunosuppressive Myeloid Components of the Tumor Microenvironment and Drives Enhanced Anti-tumor Efficacy in Combination with Anti-PD1 Antibody
Poster Presentation
Keystone Symposia Conference – Cancer Immunotherapy: Combinations
Montreal

November 2017
Increasing the Levels of Anti-beta Glucan Antibodies by Administration of Intravenous Immunoglobulin (IVIG) Induces Immunopharmacodynamic (IPD) Responses of a Novel Immunotherapeutic Imprime PGG
Poster Presentation
Society for Immunotherapy of Cancer (SITC) annual meeting
National Harbor, MD

Imprime PGG, a Novel Phase 2 Immunotherapeutic, Enhances the Anti-tumor Activity of Checkpoint Inhibitors (CPI) and Suppresses CPI-induced Indoleamine 2,3-dioxygenase (IDO) Expression
Poster Presentation
Society for Immunotherapy of Cancer (SITC) annual meeting
National Harbor, MD

October 2017
Imprime PGG, a Soluble Yeast β-glucan PAMP, Activates Both Innate and Aadaptive Immune Effector Cells, Resulting in Enhanced Antitumor Responses that Synergize with Anti-PD-1 Antibody Therapy
Poster Presentation
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications
Philadelphia

Imprime PGG Plus Pembrolizumab (PEM): a Phase 2 Immunotherapeutic Combination in Patients Selected for an Imprime-specific Biomarker
Poster Presentation
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications
Philadelphia

Imprime PGG, a Soluble Yeast β-glucan PAMP, Synergizes with Anti-PD-1 Antibody to Enhance CD8 T Cell Anti-tumor Immunity
Poster Presentation
AACR Tumor Immunology and Immunotherapy Conference
Boston

June 2017
A Multicenter, Open-label, Phase II Study of Imprime PGG (PGG Beta-Glucan) and Pembrolizumab in Patients with Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors or Triple Negative Breast Cancer Failing Front-line Chemotherapy for Metastatic Disease
Poster Presentation
American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago

April 2017
Imprime PGG Modulates Immunosuppressive Myeloid Components of the Tumor Microenvironment and Drives Enhanced Anti-tumor Efficacy in Combination with Checkpoint Inhibitor Therapies
Poster presentation
American Association for Cancer Research (AACR) Annual Meeting
Washington, DC

Imprime PGG, a Novel Innate Immune Therapeutic in Phase 2 Clinical Development, Induces Mobilization of Monocytes and Focalized Recruitment of Innate Immune Cells to Tumor Sites
Poster presentation
American Association for Cancer Research (AACR) Annual Meeting
Washington, DC

A Novel Tumor Vaccine Platform: Direct Conjugation of Antigens to the β-glucan PAMP Imprime PGG Enhances Antigen Presentation and T Cell Priming
Poster presentation
American Association for Cancer Research (AACR) Annual Meeting
Washington, DC

March 2017
A Randomized, Open-label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of BTH1677 (1,31,6 Beta Glucan; Imprime PGG) in Combination with Cetuximab and Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
Peer-reviewed paper
Investigational New Drugs, 35(3), 345-358

February 2017
Imprime PGG Drives Innate Immune Activating Pharmacodynamic Changes in a Phase I Clinical Study in Healthy Human Volunteers
Poster presentation
American Society of Clinical Oncology (ASCO) – Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium
Orlando, FL, USA